In the preceding three months, 14 analysts have released ratings for Illumina (NASDAQ:ILMN), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $166.5, a high estimate of $252.00, and a low estimate of $124.00. This current average represents a 0.1% decrease from the previous average price target of $166.67.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of Illumina by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Illumina's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Illumina analyst ratings.

Get to Know Illumina Better

Understanding the Numbers: Illumina's Finances

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Challenges: Illumina's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -5.44%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Illumina's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -178.78%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Illumina's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -55.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Illumina's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.66%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Illumina's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.